<div id="cke_pastebin">
<p>
<strong>British pharma giant AstraZeneca Plc said on Sunday that a review of safety data covering more than 17 million people vaccinated with its COVID-19 vaccine has shown no evidence of an increased risk of blood clots.</strong></p>
<p>
The vaccine is also produced at the Serum Institute of India factory in Pune and is being successfully used in India&rsquo;s vaccination campaign.&nbsp;</p>
<p>
AstraZeneca&rsquo;s review, which covered people vaccinated in the United Kingdom and European Union, comes after health authorities in some countries suspended the use of its vaccine citing cases of clotting.</p>
<p>
&ldquo;A careful review of all available safety data of more than 17 million people vaccinated in the European Union and UK with COVID-19 Vaccine AstraZeneca has shown no evidence of an increased risk of pulmonary embolism, deep vein thrombosis or thrombocytopenia, in any defined age group, gender, batch or in any particular country,&rdquo; AstraZeneca said.</p>
<p>
European Medicines Agency and the World Health Organisation have already said there is no indication that the events were caused by the vaccination, a view that was echoed by the on Friday.</p>
<p>
Denmark, the Netherlands, Norway and Ireland have suspended the use of the vaccine over clotting issues, while Austria stopped using a batch of AstraZeneca shots last week while investigating a death from coagulation disorders.</p>
<p>
&ldquo;It is most regrettable that countries have stopped vaccination on such &lsquo;precautionary&rsquo; grounds: it risks doing real harm to the goal of vaccinating enough people to slow the spread of the virus, and to end the pandemic,&rdquo; Peter English, a retired British government consultant in communicable disease control, told Reuters.</p>
<p>
The drugmaker said, 15 events of deep vein thrombosis and 22 events of pulmonary embolism have been reported so far, which is similar across other licensed COVID-19 vaccines.</p>
<p>
The company said additional testing has and is being conducted by the company and the European health authorities and none of the re-tests have shown cause for concern. The monthly safety report will be made public on the EMA website in the following week, AstraZeneca said.</p>
<p>
The AstraZeneca vaccine, developed in collaboration with Oxford University, has been authorised for use in the European Union and many countries but not yet by U.S. regulators.</p>
<p>
The company is preparing to file for U.S. emergency use authorisation and is expecting data from its U.S. Phase III trial to be available in the coming weeks.</p>
</div>
Protest demonstrations broke out across different areas of Pakistan-occupied Gilgit-Baltistan after Friday prayers, with thousands…
Jamil Maqsood, the President of the Foreign Affairs Committee of the United Kashmir People's National…
The 6th meeting of the ASEAN-India Trade in Goods Agreement (AITIGA) Joint Committee concluded in…
The US Department of Homeland Security (DHS), on behalf of the Forced Labor Enforcement Task…
A delegation from the Tibetan Parliament-in-Exile (TPiE), led by Speaker Khenpo Sonam Tenphel and accompanied…
On the sidelines of the 2nd India-CARICOM Summit, leaders of the member countries witnessed a…